19-05-2025
Conference MDAngle: ASCO 2025 Advanced NSCLC
Preconference Considerations
ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC
Dr Preeshagul notes how excitement is building around new therapies for advanced NSCLC at ASCO 2025, especially for KRAS G12C, EGFR exon 20 insertions, and HER2 alterations, with several promising studies such as LOXO-RAS-20001 and zipalertinib monotherapy drawing attention. Emerging HER2-targeted small molecules such as zongertinib and BAY 2927088 are also being closely watched for their potential central nervous system activity. Additionally, antibody-drug conjugates such as those in the TROPION-Lung02 trial are generating interest for their potential roles across treatment lines. Quick Clinical Takeaways
Coming soon: Dr Preeshagul highlights new data and progress regarding advanced NSCLC immediately following ASCO. How Will My Patients Benefit?
Coming soon: Reflections from Dr Preeshagul on how new data from ASCO will affect her patients with advanced NSCLC. Image 1: Memorial Sloan Kettering Cancer Center
